rheumatoid arthritis glp 1 GLP-1 RA Use Improves Disease Activity, Cardiovascular Risk in GLP-1 & Rheumatoid Arthritis: Clinical
Description
The rationale for a GLP-1 drug is its powerful body-wide and brain anti-inflammatory properties, says Eric Topol, a cardiologist and the director of the La Jolla, California-based Scripps Research Translational Institute, which is sponsoring the trial
Room-temperature allowances vary significantly between GLP-1 medications
Evan Nadler about what childhood obesity really is: a biologic, metabolic diseasenot a willpower problem and not a failure of parenting
When you're eating less, the efficiency of your digestion matters more, not less
No, retatrutide remains in phase 3 trials as of January 2026 and is not FDAapproved
